NASDAQ : ALZN
Alzamend Neuro, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.84M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.12M | 5.14M | 3.08M | 3.48M | 7.42M | 7.12M |
| Research & Development | 2.97M | 3.63M | 1.41M | 6.46M | 7.45M | 5.20M |
| Operating Expenses | 9.09M | 8.77M | 4.50M | 9.94M | 14.87M | 12.32M |
| Operating Income | -9.09M | -8.77M | -4.50M | -9.94M | -14.87M | -12.32M |
| Interest Expense | -6.14K | -6.62K | -18.03K | -10.10K | -7.70K | -46.52K |
| Interest & Investment Income | 1.48K | 1.08K | ||||
| EBT Excluding Unusual Items | -9.10M | -8.77M | -4.51M | -9.95M | -14.88M | -12.37M |
| Other Unusual Items | 4.00K | |||||
| Pretax Income | -9.10M | -8.77M | -4.51M | -9.95M | -14.88M | -12.36M |
| Net Income | -9.10M | -8.77M | -4.51M | -9.95M | -14.88M | -12.36M |
| Preferred Dividends & Other Adjustments | 590.23K | |||||
| Net Income to Common | -9.10M | -8.77M | -5.11M | -9.95M | -14.88M | -12.36M |
| Shares Outstanding (Basic) | 3.93M | 3.34M | 450.80K | 75.17K | 72.24K | 66.00K |
| Shares Outstanding (Diluted) | 3.93M | 3.34M | 450.80K | 75.17K | 72.24K | 66.00K |
| EPS (Basic) | -2.31 | -2.63 | -11.32 | -132.33 | -205.97 | -187.31 |
| EPS (Diluted) | -2.31 | -2.63 | -11.32 | -132.33 | -205.97 | -187.31 |
| Free Cash Flow | -6.84M | -8.07M | -6.87M | -8.42M | -8.92M | -6.72M |
| Free Cash Flow Per Share | -1.74 | -2.42 | -15.24 | -111.97 | -123.53 | -101.83 |
| EBITDA | -8.98M | -8.66M | -4.45M | -9.89M | -14.85M | -12.32M |
| D&A For EBITDA | 110.74K | 110.74K | 50.74K | 50.74K | 23.07K | 3.55K |
| EBIT | -9.09M | -8.77M | -4.50M | -9.94M | -14.87M | -12.32M |
Balance sheet
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.59M | 710.69K | 3.95M | 376.05K | 5.14M | 14.06M |
| Cash & Short-Term Investments | 7.59M | 710.69K | 3.95M | 376.05K | 5.14M | 14.06M |
| Prepaid Expenses | 663.44K | 1.05M | 228.72K | 79.19K | 694.92K | 349.72K |
| Total Current Assets | 8.25M | 1.76M | 4.18M | 455.24K | 5.84M | 14.41M |
| Property, Plant & Equipment | 287.18K | 314.87K | 425.61K | 176.35K | 79.84K | 102.91K |
| Total Assets | 8.54M | 2.08M | 4.60M | 631.59K | 5.92M | 14.52M |
| Accounts Payable | 2.74M | 1.35M | 634.76K | 2.93M | 2.87M | 1.16M |
| Short-Term Debt | 300.71K | |||||
| Other Current Liabilities | 2.08K | |||||
| Total Current Liabilities | 2.74M | 1.35M | 634.76K | 3.23M | 2.87M | 1.16M |
| Total Liabilities | 2.74M | 1.35M | 634.76K | 3.23M | 2.87M | 1.16M |
| Common Stock | 482.00 | 425.00 | 78.00 | 8.00 | 65.00 | 9.55K |
| Additional Paid-In Capital | 76.14M | 68.04M | 62.50M | 51.43M | 62.00M | 57.42M |
| Retained Earnings | -70.33M | -67.31M | -58.54M | -54.02M | -44.07M | -29.19M |
| Comprehensive Income & Other | 1.00 | -14.88M | -14.88M | |||
| Total Common Equity | 5.80M | 733.21K | 3.97M | -2.59M | 3.05M | 13.35M |
| Shareholders' Equity | 5.80M | 733.21K | 3.97M | -2.59M | 3.05M | 13.35M |
| Total Liabilities & Equity | 8.54M | 2.08M | 4.60M | 631.59K | 5.92M | 14.52M |
| Total Debt | 300.71K | |||||
| Net Cash (Debt) | 7.59M | 710.69K | 3.95M | 75.33K | 5.14M | 14.06M |
| Net Cash Per Share | 1.93 | 0.21 | 8.76 | 1.00 | 71.17 | 213.10 |
| Filing Date Shares Outstanding | 4.83M | 4.79M | 2.90M | 93.47K | 71.81K | 70.73K |
| Total Common Shares Outstanding | 4.83M | 4.26M | 778.73K | 76.44K | 71.81K | 70.73K |
| Working Capital | 5.52M | 418.35K | 3.54M | -2.77M | 2.97M | 13.25M |
| Book Value Per Share | 1.20 | 0.17 | 5.10 | -33.94 | 42.41 | 188.78 |
| Tangible Book Value | 5.80M | 733.21K | 3.97M | -2.59M | 3.05M | 13.35M |
| Tangible Book Value Per Share | 1.20 | 0.17 | 5.10 | -33.94 | 42.41 | 188.78 |
Cash flow statement
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -9.10M | -8.77M | -4.51M | -9.95M | -14.88M | -12.36M |
| Depreciation & Amortization | 110.74K | 110.74K | 50.74K | 50.74K | 23.07K | 3.55K |
| Stock-Based Compensation | 741.82K | 707.53K | 325.11K | 955.63K | 3.58M | 4.41M |
| Other Operating Activities | 9.29K | 714.00 | 8.77K | |||
| Change in Accounts Payable | 1.76M | 711.39K | -2.29M | 54.94K | 1.71M | 693.58K |
| Change in Other Net Operating Assets | -355.48K | -825.09K | -149.53K | 615.73K | 642.05K | 633.60K |
| Operating Cash Flow | -6.84M | -8.07M | -6.57M | -8.27M | -8.92M | -6.61M |
| Capital Expenditures | -300.00K | -147.24K | -106.46K | |||
| Investing Cash Flow | -300.00K | -147.24K | -106.46K | |||
| Short-Term Debt Issued | 300.00K | |||||
| Total Debt Issued | 300.00K | |||||
| Short-Term Debt Repaid | -58.67K | |||||
| Total Debt Repaid | -58.67K | |||||
| Net Debt Issued (Repaid) | 300.00K | -58.67K | ||||
| Issuance of Common Stock | 1.46M | 794.84K | 2.70M | 1.25M | 200.00 | 18.91M |
| Financing Cash Flow | 8.81M | 4.83M | 10.44M | 3.65M | 200.00 | 18.85M |
| Net Cash Flow | 1.97M | -3.24M | 3.57M | -4.76M | -8.92M | 12.13M |
| Free Cash Flow | -6.84M | -8.07M | -6.87M | -8.42M | -8.92M | -6.72M |
| Free Cash Flow Per Share | -1.74 | -2.42 | -15.24 | -111.97 | -123.53 | -101.83 |
| Levered Free Cash Flow | -3.43M | -4.78M | -5.19M | -4.69M | -4.33M | -2.19M |
| Unlevered Free Cash Flow | -3.43M | -4.77M | -5.17M | -4.68M | -4.33M | -2.16M |
| Change in Working Capital | 1.40M | -113.70K | -2.44M | 670.67K | 2.35M | 1.33M |
Ratios
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 5.84M | 4.34M | 4.36M | 4.88M | 53.05M | 94.88M |
| Enterprise Value | -1.75M | 1.62M | 1.00M | 5.01M | 45.68M | 83.09M |
| Last Close Price | 1.21 | 1.14 | 5.94 | 63.99 | 738.85 | 1,377.00 |
| PB Ratio | 1.01 | 5.92 | 1.10 | -1.88 | 17.42 | 7.11 |
| P/TBV Ratio | 1.01 | 5.92 | 1.10 | 17.42 | 7.11 | |
| Debt / Equity Ratio | -0.12 | |||||
| Net Debt / Equity Ratio | -1.31 | -0.97 | -0.99 | 0.03 | -1.69 | -1.05 |
| Net Debt / EBITDA Ratio | 0.84 | 0.08 | 0.89 | 0.01 | 0.35 | 1.14 |
| Net Debt / FCF Ratio | 1.11 | 0.09 | 0.57 | 0.01 | 0.58 | 2.09 |
| Quick Ratio | 2.77 | 0.53 | 6.22 | 0.12 | 1.79 | 12.07 |
| Current Ratio | 3.01 | 1.31 | 6.58 | 0.14 | 2.03 | 12.37 |
| Return on Equity (ROE) | -163.23% | -373.18% | -657.17% | -4,408.31% | -181.47% | -160.92% |
| Return on Assets (ROA) | -76.44% | -163.99% | -107.38% | -189.73% | -90.97% | -88.35% |
| Return on Capital Employed (ROCE) | -156.70% | -1,195.70% | -113.30% | 383.10% | -488.30% | -92.30% |
| Earnings Yield | -191.28% | -202.25% | -103.51% | -203.75% | -28.04% | -13.03% |
| FCF Yield | -117.20% | -186.01% | -157.47% | -172.40% | -16.82% | -7.08% |
| Buyback Yield / Dilution | -311.13% | -640.27% | -499.67% | -4.07% | -9.45% | -22.64% |